An overview of the diagnosis and treatment of erectile dysfunction

Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Qual...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2006-01, Vol.66 (18), p.2339-2355
Hauptverfasser: SIVALINGAM, Sivaprakasam, HASHIM, Hashim, SCHWAIBOLD, Hartwig
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2355
container_issue 18
container_start_page 2339
container_title Drugs (New York, N.Y.)
container_volume 66
creator SIVALINGAM, Sivaprakasam
HASHIM, Hashim
SCHWAIBOLD, Hartwig
description Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.
doi_str_mv 10.2165/00003495-200666180-00006
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68262732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200506909</galeid><sourcerecordid>A200506909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</originalsourceid><addsrcrecordid>eNptkV1PHCEUhomp0fXjL5hJTL0b5WOB4XLd2NrExBt7TRg4KM0MWJjV-O_LdFdNk3Iu4JzzvOTAi1BD8CUlgl_huthS8ZZiLIQgHW7nkthDC0Kkaoni-AtaYExoW_vyEB2V8mtOFVcH6JBI0hEmxQJdr2KTXiC_BHhtkm-mJ2hcMI8xlVAaE10zZTDTCHGa25DBTmGozFvxm1jPKZ6gfW-GAqe7_Rj9_HbzsL5t7-6__1iv7lq7JHhqu14QS4hjgA2VkljquVG0w4ab3lvv7NIJB4xh73rppWV9z7gUVlEBYDp2jC629z7n9HsDZdJjKBaGwURIm6JFRwWVjFbwfAs-mgF0iD5N2dgZ1qv6YRwLhVWlLv9D1XAwBpsi-PrOfwXdVmBzKiWD1885jCa_aYL1bIt-t0V_2PK3JKr0bDf6ph_BfQp3PlTg6w4wxZrBZxNtKJ9ct6S8DsH-AAFjk9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68262732</pqid></control><display><type>article</type><title>An overview of the diagnosis and treatment of erectile dysfunction</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>SIVALINGAM, Sivaprakasam ; HASHIM, Hashim ; SCHWAIBOLD, Hartwig</creator><creatorcontrib>SIVALINGAM, Sivaprakasam ; HASHIM, Hashim ; SCHWAIBOLD, Hartwig</creatorcontrib><description>Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.2165/00003495-200666180-00006</identifier><identifier>PMID: 17181376</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Androgens - therapeutic use ; Biological and medical sciences ; Constriction ; Cost of Illness ; Dopamine Agonists - therapeutic use ; Erectile Dysfunction - diagnosis ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - surgery ; Erectile Dysfunction - therapy ; Exercise Therapy ; Genital system. Reproduction ; Health Care Costs ; Hormone Replacement Therapy ; Humans ; Incidence ; Male ; Medical History Taking ; Medical sciences ; Pelvic Floor ; Pharmacology. Drug treatments ; Phosphodiesterase Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Psychotherapy - methods ; Referral and Consultation ; Severity of Illness Index ; Surveys and Questionnaires ; Urologic Surgical Procedures, Male ; Vacuum ; Vasodilator Agents - therapeutic use</subject><ispartof>Drugs (New York, N.Y.), 2006-01, Vol.66 (18), p.2339-2355</ispartof><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2006 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</citedby><cites>FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18425690$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17181376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SIVALINGAM, Sivaprakasam</creatorcontrib><creatorcontrib>HASHIM, Hashim</creatorcontrib><creatorcontrib>SCHWAIBOLD, Hartwig</creatorcontrib><title>An overview of the diagnosis and treatment of erectile dysfunction</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><description>Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.</description><subject>Androgens - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Constriction</subject><subject>Cost of Illness</subject><subject>Dopamine Agonists - therapeutic use</subject><subject>Erectile Dysfunction - diagnosis</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - surgery</subject><subject>Erectile Dysfunction - therapy</subject><subject>Exercise Therapy</subject><subject>Genital system. Reproduction</subject><subject>Health Care Costs</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical History Taking</subject><subject>Medical sciences</subject><subject>Pelvic Floor</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Psychotherapy - methods</subject><subject>Referral and Consultation</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires</subject><subject>Urologic Surgical Procedures, Male</subject><subject>Vacuum</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkV1PHCEUhomp0fXjL5hJTL0b5WOB4XLd2NrExBt7TRg4KM0MWJjV-O_LdFdNk3Iu4JzzvOTAi1BD8CUlgl_huthS8ZZiLIQgHW7nkthDC0Kkaoni-AtaYExoW_vyEB2V8mtOFVcH6JBI0hEmxQJdr2KTXiC_BHhtkm-mJ2hcMI8xlVAaE10zZTDTCHGa25DBTmGozFvxm1jPKZ6gfW-GAqe7_Rj9_HbzsL5t7-6__1iv7lq7JHhqu14QS4hjgA2VkljquVG0w4ab3lvv7NIJB4xh73rppWV9z7gUVlEBYDp2jC629z7n9HsDZdJjKBaGwURIm6JFRwWVjFbwfAs-mgF0iD5N2dgZ1qv6YRwLhVWlLv9D1XAwBpsi-PrOfwXdVmBzKiWD1885jCa_aYL1bIt-t0V_2PK3JKr0bDf6ph_BfQp3PlTg6w4wxZrBZxNtKJ9ct6S8DsH-AAFjk9Q</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>SIVALINGAM, Sivaprakasam</creator><creator>HASHIM, Hashim</creator><creator>SCHWAIBOLD, Hartwig</creator><general>Adis International</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>An overview of the diagnosis and treatment of erectile dysfunction</title><author>SIVALINGAM, Sivaprakasam ; HASHIM, Hashim ; SCHWAIBOLD, Hartwig</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-8b61c11d3e0a2771c2f5a9280a5abfcfdc4d6de330fdb7f7c3bb3576c926eea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Androgens - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Constriction</topic><topic>Cost of Illness</topic><topic>Dopamine Agonists - therapeutic use</topic><topic>Erectile Dysfunction - diagnosis</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - surgery</topic><topic>Erectile Dysfunction - therapy</topic><topic>Exercise Therapy</topic><topic>Genital system. Reproduction</topic><topic>Health Care Costs</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical History Taking</topic><topic>Medical sciences</topic><topic>Pelvic Floor</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Psychotherapy - methods</topic><topic>Referral and Consultation</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires</topic><topic>Urologic Surgical Procedures, Male</topic><topic>Vacuum</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SIVALINGAM, Sivaprakasam</creatorcontrib><creatorcontrib>HASHIM, Hashim</creatorcontrib><creatorcontrib>SCHWAIBOLD, Hartwig</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SIVALINGAM, Sivaprakasam</au><au>HASHIM, Hashim</au><au>SCHWAIBOLD, Hartwig</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An overview of the diagnosis and treatment of erectile dysfunction</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><addtitle>Drugs</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>66</volume><issue>18</issue><spage>2339</spage><epage>2355</epage><pages>2339-2355</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>Epidemiological studies have demonstrated an age-stratified increase in the incidence and prevalence of erectile dysfunction (ED). There is a greater degree of openness today when discussing sexual matters and more information on the treatment of ED is available to the public through the media. Quality-of-life issues are now a matter of great importance to the aging population. Men and their partners are no longer prepared to merely accept ED as a natural consequence of aging. The advent of a simple and effective oral therapy for ED has also indirectly fueled the increase in treatment-seeking behaviour among men. Despite great strides in research into ED, our knowledge and understanding of the pathophysiological mechanisms is still in its infancy. As a result, we are able to treat only the symptom of ED rather than prevent it. Common diseases found in the population, such as diabetes mellitus and coronary artery disease appear to be risk factors for the development of ED. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting 'the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. Efforts need to be made to uncover and address the presence of any psychological stressors, if necessary with the help of a psychosexual therapist. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>17181376</pmid><doi>10.2165/00003495-200666180-00006</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-6667
ispartof Drugs (New York, N.Y.), 2006-01, Vol.66 (18), p.2339-2355
issn 0012-6667
1179-1950
language eng
recordid cdi_proquest_miscellaneous_68262732
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Androgens - therapeutic use
Biological and medical sciences
Constriction
Cost of Illness
Dopamine Agonists - therapeutic use
Erectile Dysfunction - diagnosis
Erectile Dysfunction - drug therapy
Erectile Dysfunction - surgery
Erectile Dysfunction - therapy
Exercise Therapy
Genital system. Reproduction
Health Care Costs
Hormone Replacement Therapy
Humans
Incidence
Male
Medical History Taking
Medical sciences
Pelvic Floor
Pharmacology. Drug treatments
Phosphodiesterase Inhibitors - therapeutic use
Practice Guidelines as Topic
Psychotherapy - methods
Referral and Consultation
Severity of Illness Index
Surveys and Questionnaires
Urologic Surgical Procedures, Male
Vacuum
Vasodilator Agents - therapeutic use
title An overview of the diagnosis and treatment of erectile dysfunction
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A36%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20overview%20of%20the%20diagnosis%20and%20treatment%20of%20erectile%20dysfunction&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=SIVALINGAM,%20Sivaprakasam&rft.date=2006-01-01&rft.volume=66&rft.issue=18&rft.spage=2339&rft.epage=2355&rft.pages=2339-2355&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.2165/00003495-200666180-00006&rft_dat=%3Cgale_proqu%3EA200506909%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68262732&rft_id=info:pmid/17181376&rft_galeid=A200506909&rfr_iscdi=true